Denali Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell DNLI and other ETFs, options, and stocks.About DNLI
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau.
CEORyan J. Watts
CEORyan J. Watts
Employees422
Employees422
HeadquartersSan Francisco, California
HeadquartersSan Francisco, California
Founded2013
Founded2013
Employees422
Employees422
DNLI Key Statistics
Market cap2.63B
Market cap2.63B
Price-Earnings ratio-5.77
Price-Earnings ratio-5.77
Dividend yield—
Dividend yield—
Average volume2.26M
Average volume2.26M
High today—
High today—
Low today—
Low today—
Open price$16.96
Open price$16.96
Volume0.00
Volume0.00
52 Week high$24.35
52 Week high$24.35
52 Week low$10.57
52 Week low$10.57
Stock Snapshot
Denali Therapeutics(DNLI) stock is priced at $16.81, giving the company a market capitalization of 2.63B. It carries a P/E multiple of -5.77.
Denali Therapeutics(DNLI) stock opened on 2025-12-18 at $16.96. The price climbed to — and dipped to —.
Denali Therapeutics(DNLI) shares are trading with a volume of 0, against a daily average of 2.26M.
During the past year, Denali Therapeutics(DNLI) stock moved between $10.57 at its lowest and $24.35 at its peak.
During the past year, Denali Therapeutics(DNLI) stock moved between $10.57 at its lowest and $24.35 at its peak.
Analyst ratings
100%
of 17 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own DNLI. This list is generated using Robinhood data, and it’s not a recommendation.